GF Fund Management’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$53.2K Buy
4,413
+1,911
+76% +$23.9K ﹤0.01% 385
2026
Q2
$42.3K Sell
2,502
-85
-3% -$1.19K ﹤0.01% 405
2026
Q1
$33.2K Buy
2,587
+312
+14% +$3.97K ﹤0.01% 449
2025
Q4
$20.5K Sell
2,275
-35
-2% -$482 ﹤0.01% 508
2025
Q3
$39.9K Sell
2,310
-298
-11% -$3.67K ﹤0.01% 418
2025
Q2
$24.5K Hold
2,608
– – ﹤0.01% 481
2025
Q1
$18.5K Buy
2,608
+469
+22% +$4.74K ﹤0.01% 510
2024
Q4
$24.9K Buy
+2,139
New +$33.4K ﹤0.01% 453

Other funds holding NTLA

GF Fund Management's NTLA Position: Q3 2026 in Review

GF Fund Management increased its Intellia Therapeutics (NTLA) stake by 76% in Q3 2026, buying an estimated $23.9K and bringing the position to 4,413 shares worth $53.2K. The position accounts for ﹤0.01% of the portfolio, ranked #385.

GF Fund Management first reported a position in NTLA in Q4 2024 and has held it in 8 quarters since. 312 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • GF Fund Management held 4,413 shares of Intellia Therapeutics worth $53.2K as of Q3 2026.
  • GF Fund Management bought 1,911 Intellia Therapeutics shares in Q3 2026, an estimated $23.9K.
  • Intellia Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #385 holding.
  • GF Fund Management first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • 312 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.